(Q37149342)

18 August 2017

1 reference

title

Targeted therapy in head and neck cancer: state of the art 2007 and review of clinical applications (English)

1 reference

18 August 2017

1 reference

1 reference

head and neck carcinoma

1 reference

Corey J Langer

1

1 reference

18 August 2017

language of work or name

English

0 references

publication date

1 June 2008

1 reference

18 August 2017

number of pages

11

1 reference

inferred from page(s)

published in

Cancer

1 reference

18 August 2017

volume

112

1 reference

18 August 2017

issue

12

1 reference

18 August 2017

page(s)

2635-2645

1 reference

Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy--results of a multicentric randomized German trial in advanced head-and-neck cancer.

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23521

A phase II study of concomitant hyperfractionated radiation therapy and double dose intra-arterial cisplatin for squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23521

The epidermal growth factor receptor mediates radioresistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23521

Epidermal growth factor receptor and tumor response to radiation: in vivo preclinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23521

Advances in the treatment of locally advanced non-nasopharyngeal squamous cell carcinoma of the head and neck region

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23521

7 January 2021

Second respiratory and upper digestive tract cancers after oral cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23521

7 January 2021

The expanding role of systemic therapy in head and neck cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23521

7 January 2021

Locoregionally advanced carcinoma of the oropharynx: conventional radiotherapy vs. accelerated hyperfractionated radiotherapy vs. concomitant radiotherapy and chemotherapy--a multicenter randomized trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23521

7 January 2021

Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23521

7 January 2021

Concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: radiation therapy oncology group phase II trial 99-14

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23521

7 January 2021

Randomized phase III trial of neoadjuvant chemotherapy in head and neck cancer: 10-year follow-up.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23521

7 January 2021

Phase II Multicenter Study of the Antiepidermal Growth Factor Receptor Monoclonal Antibody Cetuximab in Combination With Platinum-Based Chemotherapy in Patients With Platinum-Refractory Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23521

7 January 2021

Phase III comparison of high-dose paclitaxel + cisplatin + granulocyte colony-stimulating factor versus low-dose paclitaxel + cisplatin in advanced head and neck cancer: Eastern Cooperative Oncology Group Study E1393

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23521

7 January 2021

A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23521

7 January 2021

Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23521

7 January 2021

An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23521

7 January 2021

Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23521

7 January 2021

Concomitant Cisplatin Significantly Improves Locoregional Control in Advanced Head and Neck Cancers Treated With Hyperfractionated Radiotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23521

7 January 2021

Radiation therapy with or without concurrent low-dose daily chemotherapy in locally advanced, nonmetastatic squamous cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23521

7 January 2021

Postoperative Concurrent Radiotherapy and Chemotherapy for High-Risk Squamous-Cell Carcinoma of the Head and Neck

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23521

7 January 2021

Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23521

7 January 2021

Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23521

7 January 2021

Intensity-modulated radiation therapy for head and neck cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23521

7 January 2021

Postoperative radiotherapy for squamous cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23521

7 January 2021

Three-dimensional conformal vs. intensity-modulated radiotherapy in head-and-neck cancer patients: comparative analysis of dosimetric and technical parameters

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23521

7 January 2021

Intensity-modulated radiation therapy use in the U.S., 2004.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23521

7 January 2021

Reassessment of the role of induction chemotherapy for head and neck cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23521

7 January 2021

Laryngeal preservation in head and neck cancer: multidisciplinary approach

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23521

7 January 2021

Induction chemotherapy with paclitaxel, cisplatin and 5-fluorouracil for squamous cell carcinoma of the head and neck: long-term results of a phase II trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23521

7 January 2021

Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23521

7 January 2021

Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23521

7 January 2021

Phase II evaluation of 96-hour paclitaxel infusion in advanced (recurrent or metastatic) squamous cell carcinoma of the head and neck (E3395): a trial of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23521

7 January 2021

Current clinical outcomes demand new treatment options for SCCHN.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23521

7 January 2021

High-dose intra-arterial cisplatin boost with hyperfractionated radiation therapy for advanced squamous cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23521

7 January 2021

Phase I/II study of docetaxel, cisplatin, and concomitant boost radiation for locally advanced squamous cell cancer of the head and neck

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23521

7 January 2021

Cetuximab in the treatment of head and neck cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23521

7 January 2021

The role of cetuximab in the treatment of squamous cell cancer of the head and neck

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23521

7 January 2021

Epidermal growth factor receptor expression on oral mucosa dysplastic epithelia and squamous cell carcinomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23521

7 January 2021

Epidermal growth factor receptor biology in head and neck cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23521

7 January 2021

Prognostic impact of the epidermal growth factor receptor levels for patients with larynx and hypopharynx cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23521

7 January 2021

Prognostic value of the epidermal growth factor receptor (EGRF) and p53 in advanced head and neck squamous cell carcinoma patients treated with induction chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23521

7 January 2021

Epidermal growth factor receptor targeting in cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23521

7 January 2021

Biological agents in head and neck cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23521

7 January 2021

EGFR-targeting monoclonal antibodies in head and neck cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23521

7 January 2021

Radiation-induced epidermal growth factor receptor nuclear import is linked to activation of DNA-dependent protein kinase

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23521

7 January 2021

The biologic effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23521

7 January 2021

Combined modality therapy of A431 human epidermoid cancer using anti-EGFr antibody C225 and radiation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23521

7 January 2021

Therapeutic potential of chimeric and murine anti-(epidermal growth factor receptor) antibodies in a metastasis model for human melanoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23521

7 January 2021

Cetuximab induce antibody-dependent cellular cytotoxicity against EGFR-expressing esophageal squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23521

7 January 2021

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23521

7 January 2021

Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23521

7 January 2021

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23521

7 January 2021

Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23521

7 January 2021

Open-Label, Uncontrolled, Multicenter Phase II Study to Evaluate the Efficacy and Toxicity of Cetuximab As a Single Agent in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Failed to Respond to Platinum-Base

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23521

7 January 2021

Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23521

7 January 2021

Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23521

7 January 2021

Inhibition of the epidermal growth factor receptor family of tyrosine kinases as an approach to cancer chemotherapy: progression from reversible to irreversible inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23521

7 January 2021

Influence of epidermal growth factor receptor (EGFR), p53 and intrinsic MAP kinase pathway status of tumour cells on the antiproliferative effect of ZD1839 ("Iressa")

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23521

7 January 2021

Enhancement of tumor radioresponse by combined treatment with gefitinib (Iressa, ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, is accompanied by inhibition of DNA damage repair and cell growth in oral cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23521

7 January 2021

Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23521

7 January 2021

Phase I study of gefitinib plus celecoxib in recurrent or metastatic squamous cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23521

7 January 2021

Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23521

7 January 2021

Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23521

7 January 2021

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23521

7 January 2021

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23521

7 January 2021

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23521

7 January 2021

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23521

7 January 2021

Interruptions adversely affect local control and survival with hyperfractionated radiation therapy of carcinomas of the upper respiratory and digestive tracts. New evidence for accelerated proliferation from Radiation Therapy Oncology Group Protocol

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23521

7 January 2021

Importance of overall treatment time for the outcome of radiotherapy of advanced head and neck carcinoma: dependency on tumor differentiation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23521

7 January 2021

Percutaneous endoscopic gastrostomy (PEG) - a long-term follow-up study in head and neck cancer patients.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23521

7 January 2021

Genomic screening of head and neck cancer and its implications for therapy planning

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23521

7 January 2021

Identifiers

DOI

10.1002/CNCR.23521

1 reference

18 August 2017

1 reference